. Author manuscript; available in PMC: 2018 Jan 3.

Published in final edited form as: Breast Cancer Res Treat. 2015 Oct 30;154(2):319–328. doi: 10.1007/s10549-015-3626-6

Table 2.

Intervention effects on clinical outcomes at 11-year (median) follow-up: multivariate Cox proportional hazards regressions and Weibull accelerated failure time models (N = 240)

Variable	All-cause mortality^b		Breast cancer-specific mortality^b		Breast cancer recurrence^c
	HR (95 % CI)	p	HR (95 % CI)	p	HR (95 % CI)	p
Study condition (CBSM)	0.21 (0.05–0.93)	.040	0.25 (0.05–1.11)	.068	0.45 (0.17–1.18)	.083
Age at diagnosis	0.91 (0.84–0.99)	.025	0.91 (0.83–0.99)	.025	0.94 (0.89–1.00)	.023
Her2/neu (positive)	2.12 (0.53–8.33)	.288	1.70 (0.39–7.41)	.481	1.85 (0.70–4.91)	.199
Tumor size
>T2	3.47 (0.40–30.13)	.259	4.81 (0.55–42.11)	.156	4.65 (0.85–25.43)	.057
T1c	1.79 (0.18–17.86)	.619	2.34 (0.23–23.89)	.474	2.89 (0.54–15.38)	.195
<T1c	–	.444	–	.306	–	–
Endocrine therapy (yes)	0.25 (0.06–0.97)	.045	0.29 (0.07–1.28)	.102	0.46 (0.16–1.29)	.121
Stage (invasive)	0.45 (0.03–7.60)	.578	–^a	–^a	0.64 (0.05–7.73)	.723

HR hazard ratio, 95 % CI 95 % confidence interval, HER2/neu human epidermal growth receptor, CBSM cognitive-behavioral stress management

Stage of disease not included in this analysis due to large standard error

Analyzed with Cox proportional hazards models

Analyzed with Weibull accelerated failure time models